ATE324905T1 - Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall - Google Patents

Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall

Info

Publication number
ATE324905T1
ATE324905T1 AT01902406T AT01902406T ATE324905T1 AT E324905 T1 ATE324905 T1 AT E324905T1 AT 01902406 T AT01902406 T AT 01902406T AT 01902406 T AT01902406 T AT 01902406T AT E324905 T1 ATE324905 T1 AT E324905T1
Authority
AT
Austria
Prior art keywords
stroke
schaemia
plgf
treat
prevent
Prior art date
Application number
AT01902406T
Other languages
English (en)
Inventor
Peter Carmeliet
Desire Collen
Original Assignee
D Collen Res Foundation Vzw
Flanders Interuniversity Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0002527A external-priority patent/GB0002527D0/en
Application filed by D Collen Res Foundation Vzw, Flanders Interuniversity Inst filed Critical D Collen Res Foundation Vzw
Application granted granted Critical
Publication of ATE324905T1 publication Critical patent/ATE324905T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pressure Vessels And Lids Thereof (AREA)
  • Dowels (AREA)
  • Clamps And Clips (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
AT01902406T 2000-02-04 2001-02-05 Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall ATE324905T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0002527A GB0002527D0 (en) 2000-02-04 2000-02-04 Use of vascular endothelial growth factor (VEGF) placental growth factor (PLGF)or both for the treatment of ischemic and acute myocardial infaction
US23659400P 2000-09-29 2000-09-29

Publications (1)

Publication Number Publication Date
ATE324905T1 true ATE324905T1 (de) 2006-06-15

Family

ID=26243563

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01902406T ATE324905T1 (de) 2000-02-04 2001-02-05 Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall

Country Status (9)

Country Link
EP (1) EP1253935B1 (de)
JP (1) JP4969753B2 (de)
AT (1) ATE324905T1 (de)
AU (2) AU4643501A (de)
DE (1) DE60119285T2 (de)
DK (1) DK1253935T3 (de)
ES (1) ES2263582T3 (de)
PT (1) PT1253935E (de)
WO (2) WO2001057181A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023863A1 (en) * 2000-04-06 2004-02-05 Franco Wayne P. Methods of use growth factors for treating heart disease
US20050026220A1 (en) * 2001-08-10 2005-02-03 Shahin Rafii Isolation and mobilization of stem cells expressing vegfr-1
ITRM20020119A1 (it) 2002-03-05 2003-09-05 Geymonat Spa Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
CA2509063C (en) * 2002-11-16 2010-11-02 Dade Behring Marburg Gmbh Scd40l and placental growth factor (plgf) as biochemical marker combinations in cardiovascular diseases
EP2295449A1 (de) 2009-09-09 2011-03-16 Dompe PHA.R.MA S.p.A. PLGF-1 in homodimerer Form
EP2948164B1 (de) * 2013-01-28 2019-04-10 Shire Human Genetic Therapies, Inc. Plazentawachstumsfaktor bei der behandlung von duchenne-muskeldystrophie

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
EP0956339B1 (de) * 1996-08-23 2005-10-12 Ludwig Institute For Cancer Research Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
NZ500530A (en) * 1997-04-25 2001-12-21 Collateral Therapeutics Truncated VEGF-B, VEGF-C, VEGF-3, PlGF, VRF-2, poxvirus ORF-1 and ORF-2 proteins
GB2332373A (en) * 1997-12-19 1999-06-23 Merck & Co Inc Treatment of coronary and/or peripheral ischemia using an antithrombotic agent and an angiogenesis promoter
CN1295617A (zh) * 1998-02-06 2001-05-16 科莱特诺医疗公司 血管生成因子－血管内皮细胞生长因子vegf的突变体

Also Published As

Publication number Publication date
PT1253935E (pt) 2006-08-31
AU2001230243A1 (en) 2001-08-14
EP1253935B1 (de) 2006-05-03
AU4643501A (en) 2001-08-14
WO2001056593A2 (en) 2001-08-09
JP2003521522A (ja) 2003-07-15
ES2263582T3 (es) 2006-12-16
WO2001057181A2 (en) 2001-08-09
DK1253935T3 (da) 2006-09-04
WO2001056593A3 (en) 2002-04-25
DE60119285D1 (de) 2006-06-08
JP4969753B2 (ja) 2012-07-04
DE60119285T2 (de) 2007-05-10
EP1253935A2 (de) 2002-11-06

Similar Documents

Publication Publication Date Title
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
MEP8209A (en) Modified factor viii
ATE531382T1 (de) Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE303156T1 (de) Verwendung von gnrh-analogue zur behandlung der harninkontinenz
EA200400482A1 (ru) Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран
DE60101265D1 (de) Behandlung von augenschmerzen
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
ATE332705T1 (de) Verwendung von in der mittlere oder späte follikuläre phase verabreichte lh zur behandlung von anovulatorischen frauen
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60119285D1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
TR200200278T2 (tr) Kalsilitik bileşimler
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
NO20026286D0 (no) Nye peptider
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
DE60209886D1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1253935

Country of ref document: EP